(MITL) Provisioning Tool And CallHosted Deliver Cloud-Based Communications Control

MiCloud Solution Enables Streamlined Web-Based Management of Communications Resources

UTRECHT, Netherlands and DORDRECHT, Netherlands, Oct. 31, 2013  — CallHosted, a leading Dutch communications service provider, is now able to extend self-care capabilities out to customers of the cloud communications service built on Mitel ® (Nasdaq:MITL) (TSX:MNW). Part of its MiCloud ‘Powered by Mitel’ solution, Mitel’s Oria Provisioning Platform provides customers with the flexibility and control of their environments required for efficient delivery and utilization of cloud based services. CallHosted was one of the first partners globally to build a service on the MiCloud platform and is now the first partner in the Netherlands to be Mitel Oria certified.

Mitel Oria is a flexible tool that allows customers to manage their own cloud communications environments by themselves, without having to rely on external resources. This allows organizations to make quick and easy changes through a standard web browser interface with no training required, on an on demand basis to support their business needs. Mitel Oria also provides efficient management tools within the Service Provider environment, including operationally aligned profiles for managing the MiCloud ‘Powered by Mitel’ solution. It offers multi-tier distribution models, back office integration into other business and operational systems, and detailed insight into the actual usage of the system. This enables partners such as CallHosted to now offer attractive ‘pay-per-use’ options.

Paul Smissaert, director at CallHosted said, “We are constantly looking for technology that is of added value for our resellers. We noticed customers want more control and to be able to do simple management themselves, like adding new users or changing access rights. Mitel Oria allows this and also gives us better insight into the usage so we can invoice the end user for what they actually use. With this technology, we want to support our resellers and bring them to the next level. These advantages made the decision to go for the certification very easy.”

Mitel Oria is part of the MiCloud ‘Powered by Mitel’ program, which offers service providers and business partners several options to deliver feature-rich cloud communications services. This includes flexible communications platforms, commercial models and optional services that align with the specific market needs and operational profile of the service provider. For more information on the MiCloud ‘Powered by Mitel’ program, please visit www.mitel.com.

About CallHosted

CallHosted offers flexible communications solutions via an extensive partner network of certified Telecom and ICT service providers. By using the smart Mitel communications and collaborations solutions, CallHosted and his partners are able to provide solutions that meet the specific customer needs. It does not matter if it is a on premise, hosted, virtualised on VMware, private cloud or hybrid solution.

About Mitel

Mitel® (Nasdaq:MITL) (TSX:MNW) is a global provider of unified communications and collaboration (UCC) software, solutions and services that enable organizations to conduct business anywhere, over any medium with the device of their choice. Through a single cloud-ready software stream, Mitel’s Freedom architecture provides customers in over 100 countries the flexibility and simplicity needed to support today’s dynamic work environment. For more information visit www.mitel.com.

MITL-C

European Contacts:

CallHosted, Angelique Adriaans Tel: +31 (0)88 003 72 34, a.adriaans@callhosted.com

Mitel, Marieke Adama, Tel: +31 (0)30 8500 030, marieke_adama@mitel.com

Whizpr, Yvon Reitsma, Tel: +31 (0)317 410 483, mitel@whizpr.nl

North American Contacts:

Amy MacLeod (media), 613-592-2122 x71245, amy_macleod@mitel.com

Malcolm Brown (industry analysts), 613-592-2122 x71246, malcolm_brown@mitel.com

Michael McCarthy (investor relations), 469-574-8134, michael_mccarthy@mitel.com

(THRM) Registers Squeeze-Out Transaction in Germany

Acquires Remaining Shares Held by Minority Shareholders

NORTHVILLE, Mich., Oct. 31, 2013 — Gentherm (NASDAQ-GS:THRM), the global market leader and developer of innovative thermal management technologies, today announced that it has registered a squeeze-out transaction in Germany and now owns 100 percent of the outstanding shares of W.E.T. Automotive Systems AG.  As a result of the squeeze-out, the remaining shares of W.E.T., representing less than one percent of W.E.T.’s outstanding shares, are transferred to Gentherm and the applicable minority shareholders are entitled to receive €90.05 per share held at the time of registration.

“With the registration of the squeeze-out complete,” said President and CEO Daniel R. Coker, “we will begin the process to delist W.E.T. as a publicly traded company in Germany.  As a result, W.E.T. will no longer be subject to and have to bear the expense of the separate reporting requirements for public companies in Germany.  The integration of the two companies is moving forward, and we are very pleased to have this important step of this process completed and behind us.”

About Gentherm

Gentherm (NASDAQ-GS:THRM) is a global developer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications. Automotive products include actively heated and cooled seat systems and cup holders, heated and ventilated seat systems, thermal storage bins, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), cable systems and other electronic devices.  The Company’s advanced technology team is developing more efficient materials for thermoelectric and systems for waste heat recovery and electrical power generation for the automotive market that may have far-reaching applications for consumer products as well as industrial and technology markets.  Gentherm has more than 7,500 employees in facilities in the U.S., Germany, Mexico, China, Canada, Japan, England, Korea, Malta, Hungary and the Ukraine.  For more information, go to www.gentherm.com.

Except for historical information contained herein, statements in this release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements regarding future business activities and decisions. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company’s actual results in future periods to differ materially from forecasted results. Those risks include, but are not limited to, risks associated with adverse conditions in the industry in which the Company operates may negatively affect its ability to complete its intended activities and carry out its business decisions. Those and other risks are described in the Company’s annual report on Form 10-K for the year ended December 31, 2012 and subsequent reports filed with the Securities and Exchange Commission (SEC), copies of which are available from the SEC or may be obtained from the Company. Except as required by law, the Company assumes no obligation to update the forward-looking statements, which are made as of the date hereof, even if new information becomes available in the future.

(FARO) to present at Baird’s 2013 Industrial Conference

LAKE MARY, Fla., Oct. 31, 2013 – FARO Technologies, Inc., (Nasdaq: FARO) the world’s most trusted source for 3D measurement, imaging and realization technology, announced today that President and CEO Jay Freeland and Senior Vice President and CFO, Keith Bair will present at the Baird’s Advanced Industrial Technologies Conference on Tuesday, November 5, 2013 at 9:00am CST at the Four Season Hotel in Chicago, IL.

The audio will be simultaneously web cast at

www.faro.com/baird-conference

FARO recommends registering at least 15 minutes prior to the start of the presentation to ensure timely access.

For more information on the FARO’s global industries, applications and products, visit www.faro.com.

About FARO

FARO is the world’s most trusted source for 3D measurement, imaging and realization technology.  The Company develops and markets computer-aided measurement and imaging devices and software. Technology from FARO permits high-precision 3D measurement, imaging and comparison of parts and compound structures within production and quality assurance processes. The devices are used for inspecting components and assemblies, production planning, documenting large volume spaces or structures in 3D, surveying and construction, as well as for investigation and reconstruction of accident sites or crime scenes.

Worldwide, approximately 15,000 customers are operating more than 30,000 installations of FARO’s systems. The Company’s global headquarters is located in Lake Mary, Fla., its European head office in Stuttgart, Germany and its Asia/Pacific head office in Singapore. FARO has branches in Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, Poland, Netherlands, India, China, Singapore, Malaysia, Vietnam, Thailand and Japan.

Further information: http://www.faro.com.

(CYTR) Further Positive Data from Global Phase 2b Clinical Soft Tissue Sarcoma Aldoxorubicin Trial

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announces further positive clinical data from a multi-site global Phase 2b study comparing the Company’s aldoxorubicin as a first-line treatment for advanced soft tissue sarcomas (STS) versus the widely used chemotherapeutic agent doxorubicin. The data is contained in a poster presented today at the 18^th Annual Connective Tissue Oncology Society Meeting at the Sheraton New York Times Square Hotel and includes additional information captured between September 27 and October 16, 2013. The study is still ongoing, and as of October 16, 2013, 47 patients remained active in the clinical trial (36 on aldoxorubicin and 11 on doxorubicin). CytRx expects to report top-line progression-free survival results for the global Phase 2b clinical trial in December 2013.

In this trial 123 patients age 18-80 years with histologically confirmed metastatic, locally advanced or unresectable soft tissue sarcomas were randomized 2:1 to receive 350 mg/m² aldoxorubicin (260 mg/m² doxorubicin equivalents) IV or 75 mg/m² doxorubicin IV every three weeks for up to six cycles.

According to the findings presented in the poster, aldoxorubicin can be administered at doses greater than 3 1/2 x the standard doxorubicin dose with similar or fewer systemic side effects. A significantly higher percentage of patients receiving aldoxorubicin are still active, have received at least 4 or 6 cycles of treatment and have a greater number of tumor responses and stable disease.

Among the findings presented today, patients in the trial treated with aldoxorubicin had a higher Overall Response Rate (ORR) (22%) compared with those treated with doxorubicin (0%) (p=0.004). In addition, a lower percentage of patients treated with aldoxorubicin (32%) showed progressive disease compared with patients treated with doxorubicin (50%) at the time of analysis.

A higher percentage of aldoxorubicin patients completed four cycles of treatment compared with doxorubicin patients (59 vs. 22, respectively) and six cycles of treatment (45 vs. 14, respectively). A similar percentage of aldoxorubicin patients (15%) and doxorubicin patients (16%) experienced neutropenic fever, and a higher percentage of doxorubicin patients (22%) had decreased cardiac output compared with aldoxorubicin patients (11%), as measured by a 15% decrease in left ventricular ejection fraction. No patient treated with aldoxorubicin had ejection fractions below 50% of their institutional norm versus 9.4% of patients that had received doxorubicin. Most importantly, there was no clinically significant reduction in cardiac function in the aldoxorubicin patients despite receiving 3 ½ times the standard dose of doxorubicin.

The poster also reported 24 serious adverse events (SAEs) associated with aldoxorubicin therapy versus 6 SAEs in patients receiving doxorubicin. All SAEs resolved and did not require treatment discontinuation. One treatment-related death in a patient treated with doxorubicin was reported.

“We are very pleased with the continued clinical findings from our global Phase 2b trial with aldoxorubicin as a first-line treatment in advanced soft tissue sarcomas, and the strength of the data presented today reinforces our belief that the linker technology platform can be applied to a broad range of cancer treatments,” said CytRx President and CEO Steven A. Kriegsman. “We look forward to advancing our aldoxorubicin second-line program into a Phase 3 pivotal trial in the first quarter of 2014 as well as evaluating aldoxorubicin as treatment for malignant glioblastoma (brain cancer) and HIV-related Kaposi’s sarcoma.”

STS is a cancer occurring in muscle, fat, blood vessels, tendons, fibrous tissues and connective tissue, and can arise anywhere in the body at any age. There are more than 30 types of STS, and according to the National Cancer Institute more than 11,410 new cases are diagnosed each year in the U.S., with 4,390 deaths. According to the Annals of Oncology, incidence of STS in Europe is approximately 4 out of every 100,000 people.

About Aldoxorubicin

The widely used chemotherapeutic agent doxorubicin is delivered systemically and is highly toxic, which limits its dose to a level below its maximum therapeutic benefit. Doxorubicin also is associated with many side effects, especially the potential for damage to heart muscle at cumulative doses greater than 500 mg/m². Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and specifically to circulating albumin, the most plentiful protein in the bloodstream. Protein-hungry tumors concentrate albumin, thus increasing the delivery of the linker molecule with the attached doxorubicin to tumor sites. In the acidic environment of the tumor, but not the neutral environment of healthy tissues, doxorubicin is released. This allows for greater doses of doxorubicin to be administered in a greater number of drug cycles while reducing its toxic side effects. In studies thus far there has been no evidence of clinically significant effects of aldoxorubicin on heart muscle, even at cumulative doses of drug well in excess of 2 g/m².

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is conducting a global Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and has completed a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. CytRx plans to initiate under a special protocol assessment a potential pivotal Phase 3 global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. CytRx also is initiating Phase 2 clinical trials with aldoxorubicin in patients with late-stage glioblastoma (brain cancer) and AIDS-related Kaposi’s sarcoma. CytRx plans to expand its pipeline of oncology candidates based on a linker platform technology that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites. CytRx also has rights to two additional drug candidates, tamibarotene and bafetinib. CytRx completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib. For more information about CytRx Corporation, visit www.cytrx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the outcome, timing and results of CytRx’s clinical trials, the risk that any future human testing of aldoxorubicin, including the conclusion of the Phase 2b clinical testing of aldoxorubicin as a first-line treatment in patients with metastatic, locally advanced or unresectable soft tissue sarcomas who have not been previously treated with any chemotherapy, might not produce objective response results similar to the preliminary data described in this press release, or might not correlate with the trial’s primary endpoint of progression-free survival, risks related to CytRx’s ability to manufacture its drug candidates in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx’s need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, including the Phase 3 clinical development of aldoxorubicin, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx’s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

(NCIT) $9.4M Air Force Data Storage and Dissemination Systems Contract

NCI, Inc. (NASDAQ:NCIT), a leading provider of information technology (IT) solutions and professional services to U.S. Federal Government agencies, announced today that it was awarded a task order under NETCENTS in the third quarter of 2013 for the development, integration, and delivery of two additional nodes of the Air Force Distributed Common Ground System (AF DCGS) Data Storage and Dissemination (DSD) system. NCI provided the first two DSD nodes under a similar contract in 2012.

The DSD accelerates data transfers across the AF DCGS network and provides storage, dissemination, processing, and retrieval capabilities to the net-centric AF DCGS enterprise. The DSD is completely redundant for fail-safe considerations, and it is anticipated that the deployment of DSD capabilities to specified locations will be used as the primary distribution method for large data files over the AF DCGS network.

“We are pleased to continue our relationship with the AF DCGS and are proud to provide solutions to the AF DCGS enterprise by bringing innovation to the warfighter and enabling battlefield readiness through affordable IT and cyber capabilities,” said Brian Clark, NCI’s President.

About NCI, Inc.:

NCI is a worldwide provider of leading-edge enterprise services and solutions to Defense, Intelligence, Healthcare, and Civilian Government agencies. Inspired by its customers’ missions and driven by their challenges, NCI helps them achieve higher levels of performance by utilizing innovative, cutting-edge technologies and methodologies in the following capability areas: Cloud Computing and IT Infrastructure Optimization; Cybersecurity and Information Assurance; Engineering and Logistics Support; Enterprise Information Management and Advanced Analytics; Health IT and Medical Support; IT Service Management; Modeling, Simulation, and Training; and Software and Systems Development/Integration.

Headquartered in Reston, Virginia, NCI has nearly 2,000 employees operating in more than 100 locations around the globe. For more information, visit www.nciinc.com or email investor@nciinc.com. Like us on Facebook and follow us on Twitter (@nciinc_) and LinkedIn.

(PRAN) PBT2 Reverses Memory Loss in Normal Aging

(OXBT) and Phyxius Pharma, New Evidence on Levosimendan in Heart Surgery Patients

Phyxius Pharma, Inc. and Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT), today announced that researchers at the Duke Clinical Research Institute (DCRI), part of the Duke University School of Medicine, recently published findings of a meta-analysis of multiple clinical trials that evaluated the use of levosimendan in patients undergoing heart surgery. The study aggregated and analyzed results from 14 independent clinical trials with a total of 1,155 patients. The published results showed that levosimendan was associated with reduced mortality (death) and other adverse outcomes including heart attacks during and after operation in patients with reduced heart function undergoing heart surgery. This research was recently published in the Journal of Cardiothoracic and Vascular Anesthesia as an “in Press” online version of the publication that precedes the final publication. A link to the online version of the publication is available here: http://www.jcvaonline.com/article/S1053-0770(13)00171-7/abstract.

Oxygen Biotherapeutics has a Definitive Agreement to acquire certain assets of Phyxius Pharma, including the U.S. and Canadian development and commercialization rights to levosimendan. The United States Food and Drug Administration (FDA) has granted Fast Track status for levosimendan for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome (LCOS). In addition, the FDA has agreed to Phyxius Pharma’s Phase 3 protocol design under Special Protocol Assessment (SPA), and provided guidance that a single successful trial will be sufficient to support approval of levosimendan in this indication.

John Alexander, M.D., MHS, Director, Cardiovascular Research, Duke Clinical Research Institute said, “Our meta-analysis of 14 randomized clinical trials suggests that levosimendan, in conjunction with standard care in high-risk cardiac surgery patients with reduced left ventricular function, may reduce mortality and other adverse outcomes by as much as 50 percent.”

John Kelley, CEO of Phyxius Pharma stated, “These findings are highly supportive of our definitive Phase 3 trial design which includes mortality, need for dialysis, peri-operative myocardial infarction, as components of the primary composite endpoint. With the support of these data and the FDA’s guidance we have designed a very modest sized and highly cost efficient trial of 760 patients. This is far smaller than other cardiac trials which typically require larger patient populations.”

Robert Harrington, M.D. Chairman of the Department of Medicine at Stanford University stated, “LCOS represents an area of unmet medical need. The results of this meta-analysis are highly supportive of Phyxius Pharma’s current Phase 3 clinical trial design that intends to evaluate the ability of levosimendan treatment to prevent LCOS and the associated mortality and morbidity.”

Consistent with the positive meta-analysis findings, the Phase 3 trial is designed to include low EF (Ejection Fraction) cardiac surgery patients and evaluates several end points included in the meta-analysis.

About Phyxius Pharma

Phyxius Pharma, Inc. is a privately-held development stage pharmaceutical company. The company is focused on developing products for use in acute care settings. The company has licensed North American rights to develop and commercialize levosimendan from Orion Pharma, Orion Corporation of Espoo, Finland.

About Levosimendan

Levosimendan is a calcium sensitizer developed for intra-venous use in hospitalized patients with acutely decompensated heart failure. It is currently approved in 53 countries for this indication. It is not available in the United States. It is under development in North America for reduction in morbidity and mortality of cardiac surgery patients at risk of low cardiac output syndrome (LCOS).

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is developing medical products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte^® that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. The company is also developing PFC-based creams and gels for topical delivery to the skin for dermatologic conditions and potentially wound care.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the Company that involve risks and uncertainties and reflect the company’s judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the likelihood of the consummation of the Phyxius transaction, as well as the successful integration of Phyxius into the Company, delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current Form 10-Q filed on September 17, 2013, and our annual report on Form 10-K filed on June 26, 2013, as well as other filings with the SEC. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

(CLPI) CEO Harold Montgomery to Present at the Sixth Annual LD Micro Cap Conference

Calpian, Inc. (OTC:CLPI), today announced that Chairman and Chief Executive Officer, Harold Montgomery, will be presenting at the Sixth Annual LD Micro Conference which will be held in Los Angeles from December 3rd through December 5^th.

Mr. Montgomery will discuss the company’s domestic operations as well as the services platform of its Indian subsidiary, Money-On-Mobile, the Indian leader in pre-paid mobile payment solutions.

About Calpian, Inc.

Calpian, Inc. (CLPI) is a publicly traded company with corporate offices in Dallas, Texas and mobile payments emerging-market operations through its subsidiary in India. Calpian’s Indian subsidiary offers Money-on-Mobile, a pre-paid mobile payment solution, to more than 163,000 Indian retail locations. Calpian’s management team has over 70 years in combined experience in the payments business. Calpian’s CEO, Harold Montgomery, is a recognized industry leader who has provided expert testimony to the U.S. Congress and Federal Reserve Bank on payments-related issues and regularly appears in numerous industry publications, such as Transaction World Magazine. Please visit our website at www.calpian.com for more information.

(AAOI) Expands Its Data Center Product Line With 40 Gbps Transceivers

SUGAR LAND, Texas, Oct. 29, 2013 — Applied Optoelectronics, Inc. (Nasdaq:AAOI), a leading provider of fiber-optic access network products for the cable broadband, internet data center, and fiber-to-the-home markets today announces a new line of short reach 40 Gbps fiber optic transceivers aimed at the data center market.

The new QSFP+SR4 transceivers utilize AOI’s proprietary silicon photonics-based optical engine technology. They employ laser and photodiode/pre-amp arrays in multi-channel links that are interoperable with other 40GBASE-SR4 QSFP+ and QDR transceivers. The MSA-compliant transceivers have an extended reach to 300 meters over OM3 fiber.

AOI also announces active optical cable assemblies (AOC’s) for data centers and core network applications, also operating at 40 Gbps. These AOC products are pre-configured with a pair of 40G transceivers, mutually conjoined by a fiber optic cable. AOI’s modules provide an industry-leading ultra high-speed interconnectivity solution for data center operators. The AOCs are also available for breakout of 40G to four individual SFP+ 10G serial ports for data centers in transition.

“The need for bandwidth in the datacenter is constantly growing. As a leading provider of internet datacenter optics, AOI has spent years developing the suite of technologies desired by our customers, who need interconnection speeds higher than the now-current 10 Gbps rate,” comments Robinson Tsai, VP of R&D for AOI’s Network Equipment Business Unit. “These technologies currently support 40 Gbps and are extensible to 100 Gbps and beyond. AOI is positioned to work closely with customers to offer a cost-effective solution with industry-leading performance and the ability to customize functions as needed for individual customer requirements.”

For more information about AOI’s complete portfolio of 40G QSFP+ transceivers, contact us by email at sales@ao-inc.com, or visit our website at www.ao-inc.com.

About Applied Optoelectronics (AOI)

Applied Optoelectronics, Inc. (Nasdaq:AAOI) is a leading, vertically-integrated provider of fiber-optic networking products, principally used in the cable television broadband, fiber-to-the-home, and internet datacenter markets. AOI was founded in 1997, and has its headquarters in Sugar Land, Texas, with additional manufacturing and R&D operations in Taipei, Taiwan and Ningbo, China. For additional information, visit www.ao-inc.com.

CONTACT: Media Enquiries:
         Willis Chen
         281/295-1807
         wchen@ao-inc.com

(MDCA) Adds Two Senior Executives to Management Team

Fast-Growing Company Enlists Former GE Executive Dennis McGuire as Senior Vice President, Treasurer, and Deutsche Bank Analyst Matt Chesler as Vice President, Investor Relations

NEW YORK, Oct. 29, 2013  — MDC Partners announced today that it has enlisted two new senior executives to bolster its management team.  Dennis McGuire is taking on the role of SVP, Treasurer for the company, while Matt Chesler joins as VP, Investor Relations.  With over 20 years of experience in treasury, corporate finance, M&A and banking, McGuire will lead and direct all corporate and Partner network treasury activities.  Chesler brings over 10 years of experience as Equity Research Analyst to MDC, where he will work alongside CFO David Doft on all investor relations activities.

“We are extremely pleased to welcome Dennis and Matt at a time of accelerated growth and international expansion for MDC,” said Doft.  “Dennis brings both impressive versatility and a broad-based skill set to the role, with not only extensive corporate treasury experience, but also significant bank-side and practical international expertise.  A strategic and veteran corporate treasury executive, he will be an enormous asset to MDC and to our Partner agencies.”

Added Doft, “Matt is one of the best senior analysts in the advertising and media space, and has a deep knowledge and understanding of our industry and of MDC’s business.  We are thrilled that he will enhance our team’s level of sophistication as the company’s market cap and business continue to grow.”

McGuire comes to MDC Partners from the General Electric Company, where he worked in Corporate Treasury for 10 years as a Managing Director and Assistant Treasurer supporting the company’s GE Capital and Industrial businesses, including GE’s former media business, NBC Universal.  Earlier in his career, McGuire held treasury leadership roles at blue-chip firms PepsiCo and Honeywell and began his career in corporate banking with Chase Manhattan Bank and Bankers Trust.

“I am extremely impressed by the progressive way in which MDC has approached all aspects of its business and by its dedication to creating best-in-class operations and services for its Partners,” said McGuire.  “This is an extraordinary opportunity to work for a truly innovative company at a particularly exciting time in its growth trajectory, and I am looking forward to adding the benefit of my experience and perspective to the team.”

Since 2003, Chesler has worked at Deutsche Bank as an analyst covering the media sector, with primary subsector responsibilities for advertising agencies, magazines, local TV, and audience measurement, and has been a lead analyst since 2008.  From 2009 to 2011, he also served as a member of the Internet & Interactive Entertainment team.  He was named an “Up and Comer” in the Publishing & Advertising sector by Institutional Investor two times in 2009 and 2010, was a member of a team that ranked third in the annual Institutional Investor survey in 2007 and that won a Wall Street Journal “Best of the Street” stock-picking award in 2005. Prior to joining Deutsche Bank in 2003, Chesler worked in the accounting industry for six years for Ernst & Young and PriceWaterhouseCoopers.

“I’ve admired MDC for a long time, and from the vantage point of an analyst, I gained a unique perspective on the industry,” said Chesler.  “I’m looking forward to now being a part of what I see as a best-in-class organization that is truly dedicated and structured to building value for its clients, agency partners and shareholders.”

About MDC Partners Inc.

MDC Partners is one of the world’s largest Business Transformation Organizations that utilizes technology, marketing communications, data analytics, insights and strategic consulting solutions to drive meaningful returns on Marketing and Communications Investments for multinational clients in the United States, Canada, and worldwide.

MDC Partners’ durable competitive advantage is to Empower the Most Talented Entrepreneurial Thought Leaders to Drive Business Success to new levels of Achievement, for both our Clients and our Shareholders, reinforcing MDC Partners’ reputation as “The Place Where Great Talent Lives.”

MDC Partners’ Class A shares are publicly traded on NASDAQ under the symbol “MDCA” and on the Toronto Stock Exchange under the symbol “MDZ.A”.

CONTACT:
Alexandra Delanghe
SVP, Corporate Communications
646-429-1845
adelanghe@mdc-partners.com

(SHLD) Kmart® Integrated Retail Services Expand To Puerto Rico

Localized Online Shopping Experience Enables New Services for Puerto Rico

HOFFMAN ESTATES, Ill., and SAN JUAN, Puerto Rico, Oct. 29, 2013 — Kmart announced today that it will extend its integrated retail shopping conveniences to customers in Puerto Rico. Kmart’s integrated retail strategy connects online and in-store shopping channels to provide more flexible ways to shop. For the first time this holiday season, Puerto Rico-based Kmart customers and Shop Your Way^SM members will have access to online layaway, store-to-home shipping, free Anyone, Anywhere pickup and free store pickup.

The expansion coincides with the launch of a localized e-commerce channel that has been created within Kmart.com. The site also allows customers in Puerto Rico to enter their zip code and shop online at Kmart.com for a relevant assortment of products.

“Kmart strives to provide a seamless experience for our customers,” said Dave Rodney, regional vice president of Kmart Puerto Rico and the U.S. Virgin Islands. “We are excited to give our Shop Your Way members and customers in Puerto Rico access to new options that enhance the experience in-store and online.”

Expanded in-store and online shopping amenities will bring added convenience to customers in Puerto Rico by giving more choices and additional ways to shop and save this holiday season. Customers will find new ways to plan holiday spending with online layaway, save time with store-to-home shipping and minimize unnecessary shipping costs with free Anyone, Anywhere pickup and free store pickup.

Online Layaway

Kmart customers and Shop Your Way members in Puerto Rico can now take advantage of online layaway as a way to plan their holiday spending. Customers can initiate a layaway contract online and choose to ship their purchases home or pick up their purchases from their selected Kmart store. Kmart shoppers can enjoy free layaway online or in-store through Nov. 23, plus free shipping on purchases $59 or more for the holidays.

Store-to-Home Shipping

Checking-off holiday shopping lists will be easier than ever as Kmart’s 23 Puerto Rico store locations will now offer free store-to-home shipping for customers and members when the product they want is not immediately available in-store.

Free Anyone, Anywhere Pickup

Free Anyone, Anywhere Pickup provides customers with a way to alleviate shipping fees as they purchase gifts online and have friends or family pick them up at a Kmart location, whether stateside or in Puerto Rico.

Free Store Pickup

Shop Your Way members can also take advantage of free store pickup while shopping at Kmart.com, featuring free same-day pick up at a local Puerto Rico store.

About Kmart

Kmart, a wholly owned subsidiary of Sears Holdings Corporation (NASDAQ: SHLD), is a mass merchandising company and part of SHOP YOUR WAY, a social shopping experience where members have the ability to earn points and receive benefits across a wide variety of physical and digital formats through ShopYourWay.com. Kmart offers customers quality products through a portfolio of exclusive brands that include Sofia by Sofia Vergara, Jaclyn Smith, Joe Boxer, Route 66 and Smart Sense. For more information visit the company’s website at www.kmart.com | Sears Holdings Corporation website at www.searsholdings.com | Facebook: www.facebook.com/kmart

(USAT) Lands Largest Commitment Ever for ePort Connect Cashless Payment and Telemetry

USA Technologies, Inc. (NASDAQ: USAT), (“USAT”), a leader of wireless, cashless payment and M2M telemetry solutions for small-ticket, self-serve retailing industries, today announced that it has received its largest purchase commitment ever. The commitment comes from USConnect®, an alliance of independent vending and food service companies throughout the United States, which is targeting the adoption of cashless payment and telemetry technologies for the majority of the self-serve locations owned or operated by its members by 2018.

The agreement calls for the purchase of 50,000 ePorts® by USConnect through its members over the next five years, all of which will utilize USAT’s comprehensive ePort Connect® suite of services.

According to Jeff Whitacre, longstanding vending operator and industry entrepreneur, USConnect is the largest connected network of independent vending and food service companies in the United States. Consisting of approximately 25 members to date, the USConnect consortium manages over 100,000 snack, food, beverage and other self-serve machines.

“The goal of USConnect is to facilitate, in a leadership role, the modernization of the vending and food service industry through cashless payment, wireless telemetry and the value-added capabilities that a connected base of self-serve terminals can provide—both now and in the future,” said Jeff Whitacre, chief executive officer and founder of USConnect. “Technology that connects people, information and machinery is changing the landscape in the self-serve retail market, and our industry needs to embrace it. We believe it’s time to re-engage the consumer and disrupt the traditional business model.”

“USConnect is taking this assertive step with USAT because we’re confident that a cashless payment and telemetry platform can deliver immense value to businesses like ours—and USAT has played a huge part in that educational process since the beginning,” continued Whitacre. “We value the reliability and flexibility of their service and their commitment to innovative technologies, services and programs that are good for business and the industry at large. We look forward to influencing the vending and food service industry in a positive way with USAT.”

“We are pleased to see USConnect, on behalf of its members, take a prominent role in the transformation of the vending industry,” said Stephen P. Herbert, chairman and chief executive officer of USA Technologies. “Our business is based on the fundamental view that the self-serve retail industry as a whole has tremendous potential to increase revenues and consumer engagement by making the transition to cashless payment. With cashless adoption in its early stages, customers like USConnect and its members are clearly positioned to take early advantage.”

About USConnect:

USConnect is a consortium of industry-leading, independent food service companies across the United States. Together, USConnect member companies provide outstanding quality fresh foods, vending and unattended retail services, along with corporate catering and coffee services as well as consistent service and state-of-the-art technology and programs to their corporate food service clients. To learn more, visit the website at www.usconnect.biz

About USA Technologies:

USA Technologies is a leader of wireless, cashless payment and M2M telemetry solutions for small-ticket, self-serve retailing industries. ePort Connect® is the company’s flagship service platform, a PCI-compliant, end-to-end suite of cashless payment and telemetry services specially tailored to fit the needs of small ticket, self-service retailing industries. USA Technologies also provides a broad line of cashless acceptance technologies including its NFC-ready ePort® G8, ePort Mobile™ for customers on the go, and QuickConnect™, an API Web service for developers. USA Technologies has been granted 86 patents; and has agreements with Verizon, Visa, Elavon and customers such as Compass, Crane, AMI Entertainment and others. Visit the website at www.usatech.com.

Forward-looking Statements:

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: All statements other than statements of historical fact included in this release, including without limitation the business strategy and the plans and objectives of USAT’s management for future operations, are forward-looking statements. When used in this release, words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, and similar expressions, as they relate to USAT or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of USAT’s management, as well as assumptions made by and information currently available to USAT’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the ability of USAT to retain key customers from whom a significant portion of its revenues is derived; whether USAT’s customers would continue to add additional connections to our network in the future at levels currently anticipated by USAT; the ability of USAT to compete with its competitors to obtain market share; whether USAT’s customers continue to utilize USAT’s transaction processing and related services, as our customer agreements are generally cancelable by the customer on thirty to sixty days’ notice; the ability of USAT to obtain widespread commercial acceptance of its products; and whether USAT’s existing or anticipated customers purchase, rent or utilize ePort devices or our cashless payment services in the future at levels currently anticipated by USAT. Readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statement made by us in this release speaks only as of the date of this release. Unless required by law, USAT does not undertake to release publicly any revisions to these forward-looking statements to reflect future events or circumstances or to reflect the occurrence of unanticipated events.

(CYTR) Reports 2013 Third Quarter Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three and nine-month periods ended September 30, 2013, and provided a clinical update.

“Our achievements during the third quarter and recent weeks position CytRx to make significant progress and create shareholder value for the remainder of 2013 and well into 2014,” said Steven A. Kriegsman, CytRx President and CEO. “With our cash position bolstered by a recent equity offering that netted approximately $24.1 million, we have the resources to continue a robust program of clinical trials with aldoxorubicin in multiple oncology indications. Later this week, we will be presenting further impressive preliminary results from our global Phase 2b clinical trial in first-line soft tissue sarcoma at the Connective Tissue Oncology Society Annual Meeting in New York.

“In the third quarter, we were excited to announce that aldoxorubicin significantly increased survival rates in mice transplanted with human glioblastoma cells in a confirmatory study, and demonstrated the ability in that study to cross the blood-brain barrier and induce key biomarkers that lead to glioblastoma tumor cell death. Glioblastoma is a deadly form of brain cancer, and we plan to initiate a Phase 2 trial later this year in patients with advanced, relapsed glioblastoma, and a Phase 2 trial in Kaposi’s sarcoma, a common HIV-associated tumor,” continued Mr. Kriegsman. “Finally, we expect to commence a global Phase 3 pivotal trial in the first quarter of 2014 to evaluate aldoxorubicin as a treatment for patients with second-line soft tissue sarcomas that have progressed following prior treatment with chemotherapy. That trial is being conducted under a special protocol assessment with progression-free survival as the primary endpoint.”

Recent Clinical Highlights

• July – reported highly favorable data from a human model of glioblastoma implanted in animals and treated with aldoxorubicin, including statistically significant efficacy and prolonged survival.
• September – announced preliminary data from the global Phase 2b soft tissue sarcoma trial showing patients treated with aldoxorubicin had an Overall Response Rate (ORR) of 22%, whereas those administered the widely used chemotherapeutic agent doxorubicin had an ORR of 0%.

Upcoming Milestones

• 4Q13 – initiate a Phase 2 trial with aldoxorubicin in patients with relapsed glioblastoma. Study site participants include The John Wayne Cancer Center in Santa Monica, Calif., the City of Hope in Duarte, Calif. and the LSU Health Science Center in New Orleans.
• 4Q13 – initiate a Phase 2 trial evaluating the preliminary efficacy of aldoxorubicin in treating AIDS-related Kaposi’s sarcoma; this trial will enroll up to 30 patients at the LSU Health Science Center.
• December 2013 – report top-line progression-free survival results from the global Phase 2b trial comparing the efficacy and safety of aldoxorubicin and doxorubicin as a first-line treatment for patients with soft tissue sarcoma.
• 1Q14 – initiate a global Phase 3 pivotal trial with aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma who have failed chemotherapy under a special protocol assessment.
• Ongoing – work to expand the oncology pipeline by combining our novel linker platform technology with additional chemotherapeutic agents.

Third Quarter 2013 Financial Results

The net loss for the third quarter of 2013 was $10.0 million, or $0.33 per share, compared with net income for the third quarter of 2012 of $1.6 million, or $0.07 per diluted share. The difference is largely attributable to the Company’s warrant derivative liabilities – In the third quarter of 2013, the Company recorded a loss of $4.0 million on warrant derivative liabilities, compared with a non-cash gain on warrant derivative liabilities of $6.4 million in the third quarter of 2012. The derivative liabilities are related to warrants issued in August 2011 and July 2009. The Company did not recognize revenue for either quarter.

Research and development (R&D) expenses were $4.0 million for the third quarter of 2013, and included aldoxorubicin development expenses of $3.3 million. R&D expenses were $3.2 million for the third quarter of 2012.

General and administrative (G&A) expenses were $2.0 million for the third quarter of 2013, compared with $1.7 million for the comparable period in 2012.

CytRx reported cash, cash equivalents and short-term investments of $23.0 million and no debt as of September 30, 2013. Subsequent to the close of the quarter, on October 15, 2013 the Company completed an underwritten public offering of common stock, raising net proceeds of approximately $24.1 million.

About Soft Tissue Sarcoma

Sarcoma is an umbrella term for more than 50 subtypes of cancer that occur in the muscles, fat, blood vessels, tendons and other connective tissues in the body. Last year an estimated 38,000 new cases of soft tissue sarcoma were reported and more than 13,000 deaths were attributed to this cancer in the U.S. and Europe. Patients with metastatic, locally advanced or unresectable soft tissue sarcomas have a poor prognosis with progression-free survival of around 2 months to 4.6 months and median overall survival of approximately 9 months to 12 months. CytRx has been granted orphan drug designation by the FDA for the treatment of patients with soft tissue sarcomas.

About Glioblastoma

Glioblastoma is the most common and most malignant brain tumor in adults and afflicts more than 12,000 new patients in the U.S. annually. Despite surgical resection, radiotherapy and chemotherapy, the median survival after diagnosis is approximately 12 months to 14 months. Although the reason for treatment failure may depend upon several factors, limited efficacy of chemotherapeutic agents has been attributed to several contributing factors including insufficient drug delivery to the tumor site through the blood-brain barrier.

About Aldoxorubicin

The widely used chemotherapeutic agent doxorubicin is delivered systemically and is highly toxic, which limits its dose to a level below its maximum therapeutic benefit. Doxorubicin also is associated with many side effects, especially the potential for damage to heart muscle at cumulative doses greater than 500 mg/m². Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and specifically to circulating albumin, the most plentiful protein in the bloodstream. Protein-hungry tumors concentrate albumin, thus increasing the delivery of the linker molecule with the attached doxorubicin to tumor sites. In the acidic environment of the tumor, but not the neutral environment of healthy tissues, doxorubicin is released. This allows for greater doses of doxorubicin to be administered while reducing its toxic side effects. In studies thus far there has been no evidence of clinically significant effects of aldoxorubicin on heart muscle, even at cumulative doses of drug well in excess of 2 g/m².

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is conducting a global Phase 2b trial with aldoxorubicin as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 trial primarily in the same indication and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and has completed a Phase 1b pharmacokinetics trial in patients with metastatic solid tumors. CytRx plans to initiate under a special protocol assessment a potential pivotal Phase 3 global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. CytRx also is initiating Phase 2 trials with aldoxorubicin in patients with late-stage glioblastoma (brain cancer) and AIDS-related Kaposi’s sarcoma. CytRx plans to expand its pipeline of oncology candidates based on a linker platform technology that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites. CytRx also has rights to two additional drug candidates, tamibarotene and bafetinib. CytRx completed its evaluation of bafetinib in the ENABLE Phase 2 trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib. For more information about CytRx Corporation, visit www.cytrx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the outcome, timing and results of CytRx’s clinical trials, the risk that any future human testing of aldoxorubicin, including the conclusion of the global Phase 2b trial testing of aldoxorubicin as a first-line treatment in patients with metastatic, locally advanced or unresectable soft tissue sarcomas who have not been previously treated with any chemotherapy, might not produce objective response results similar to the preliminary data described in this press release, or might not correlate with the trial’s primary endpoint of progression-free survival, risks related to CytRx’s ability to manufacture its drug candidates in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx’s need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, including the Phase 3 clinical development of aldoxorubicin, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx’s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

(HOTR) Appoints Richard Adams President, COO of American Roadside Burgers

Brings on Thomas Lewison as Chanticleer Holdings’ Strategic Advisor — Continues to Build World Class Leadership Team

Brings on Thomas Lewison as Chanticleer Holdings’ Strategic Advisor — Continues to Build World Class Leadership Team

(USAT) to Showcase ePortGO at the TLPA 95th Annual Convention

USA Technologies, Inc. (NASDAQ: USAT), (“USAT”), a leader of wireless, cashless payment and M2M telemetry solutions for small-ticket, self-serve retailing industries, today announced that it will be showcasing its new, all-in-one solution for the taxi and for-hire vehicle industry—ePortGO™—at the Taxi, Limousine and Paratransit Association’s (“TLPA”) 95th Annual Convention & Trade Show in Boston, October 27-31, 2013, in the Verizon Wireless booth, Number 120.

Designed to turn a smartphone into a dynamic business terminal, ePortGO is a fully integrated transport system that enables credit/debit card fare payment, trip management, recordkeeping, vehicle dispatching, navigation, and other features. It’s an easily scalable and cost-effective solution that essentially eliminates the need for costly, multi-hardware investments, redundant processes and higher “card not present” processing rates.

ePortGO is available for one monthly fee per device for Android smartphones or tablets. Standard features of ePortGO include:

• Integrated recordkeeping
• Reconciliation
• Web-based reports
• Taximeter integration
• In-vehicle credit/debit card acceptance
• 24 x 7 customer service and support

Premium features include:

• ePortGO’s standard features, plus
• Cloud-based dispatch system
• Reservation capability
• Integrated GPS navigation and driver tracking
• Branded passenger mobile app

View Product Overview video, or visit www.ePortGO.com.

ePortGO links software specifically designed for the taxi and for-hire vehicle industries with USAT’s ePort Mobile™ solution for secure credit/debit card mobile acceptance and USAT’s comprehensive cashless payment service, ePort Connect®. ePort Connect handles all aspects of credit/debit card acceptance—from merchant account setup to credit/debit card reconciliation and settlement to sales reporting and customer service—making it easy for businesses to implement and maintain their cashless payment offering. ePort Connect includes the Verizon Wireless network for connectivity.

According to the TLPA, the TLPA Annual Convention trade show is the largest trade show for for-hire transportation fleet owners in the taxicab, limousine & paratransit industry. The TLPA Annual Convention trade show is where leading industry vendors showcase and introduce the most advanced products, services, technologies and solutions to key decision makers. The TLPA’s 95^th Annual Convention and Trade Show will be held at the John B. Hynes Veterans Memorial Convention Center, Boston, Massachusetts, from October 27-31, 2013. For more information, visit http://www.tlpa.org/meetings/13annual_convention.cfm.

About USA Technologies:

USA Technologies is a leader of wireless, cashless payment and M2M telemetry solutions for small-ticket, self-serve retailing industries. ePort Connect® is the company’s flagship service platform, a PCI-compliant, end-to-end suite of cashless payment and telemetry services specially tailored to fit the needs of small ticket, self-service retailing industries. USA Technologies also provides a broad line of cashless acceptance technologies including its NFC-ready ePort® G8, ePort Mobile™ for customers on the go, and QuickConnect™, an API Web service for developers. USA Technologies has been granted 86 patents; and has agreements with Verizon, Visa, Elavon and customers such as Compass, Crane, AMI Entertainment and others. Visit the website at www.usatech.com.

Forward-looking Statements:

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: All statements other than statements of historical fact included in this release, including without limitation the business strategy and the plans and objectives of USAT’s management for future operations, are forward-looking statements. When used in this release, words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, and similar expressions, as they relate to USAT or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of USAT’s management, as well as assumptions made by and information currently available to USAT’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the ability of USAT to compete with its competitors to obtain market share; whether USAT’s customers continue to utilize USAT’s transaction processing and related services, as our customer agreements are generally cancelable by the customer on thirty to sixty days’ notice; whether USAT’s existing or anticipated customers purchase, rent or utilize ePort devices, including the ePortGO, or our cashless payment services in the future at levels currently anticipated by USAT; the ability of USAT to use available data to accurately predict future market conditions, consumer behavior and any level of cashless usage; whether the features and operation of the ePortGO fully comply with the legal requirements of local taxicab agencies; the ability of USAT to obtain licenses to sell or rent the ePortGO from local taxicab agencies, where mandated; and the ability of USAT to operate without infringing the proprietary rights of others. Readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statement made by us in this release speaks only as of the date of this release. Unless required by law, USAT does not undertake to release publicly any revisions to these forward-looking statements to reflect future events or circumstances or to reflect the occurrence of unanticipated events.

(PME) Independent Members of Board Approves Sale of Dredging Subsidiary for $365.5M

Board of Directors Receives Independent Fairness Opinion from Duff and Phelps, LLC

FUZHOU, China, Oct. 28, 2013 – Pingtan Marine Enterprise Ltd. (Nasdaq: PME), (“Pingtan,” or the “Company”) an integrated marine services company in the People’s Republic of China (PRC), today announced that the independent members of the Company’s Board of Directors (“the Board”) have agreed to sell Pingtan’s 100% owned dredging subsidiary, China Dredging Group (“CDGC”) and its PRC operating subsidiaries, Fujian Xing Gang Port Service Co., Ltd. business and operating assets to an affiliate of the Company’s Chairman, CEO and majority shareholder Mr. Xinrong Zhuo.

Highlights

• In addition to the fairness opinion on the proposed transaction from Duff and Phelps, LLC, the Board received appraisal reports from BMI Appraisals Limited (“BMI”) for the respective operating rights and licenses to conduct fishing services of 20 new vessels which are included as part of transaction consideration (available on the Company’s website, www.ptmarine.com).
• The Board, excluding Chairman and CEO Mr. Xinrong Zhuo, and the Company’s Senior Officer, Mr. Bin Lin, unanimously approved moving forward with the transaction.
• During a period of 30 days from the date of this press release, the Board, excluding Mr. Zhuo and Mr. Lin, will evaluate other alternative proposals received.
• The transaction is expected to close during the fourth quarter of 2013.

Terms and Background of the Transaction

Under the terms of the proposed transaction, the consideration to be received by the Company consists of:

(i) forgiveness of the Company’s current $155.2 million 4% promissory note due on June 19, 2015; and

(ii) the transfer to the Company of the 25-year exclusive operating rights (see description of operating rights below) for 20 new fishing vessels, with such rights appraised at $216.1 million by BMI as described below.

As previously announced on July 29, 2013, the Board received an offer from its Chairman and CEO, Mr. Xinrong Zhuo for CDGC. At that time the Board, excluding Chairman and CEO Mr. Xinrong Zhuo, and the Company’s Senior Officer, Mr. Bin Lin, retained Duff & Phelps LLC, as its independent financial advisor and investment banking firm, to provide an opinion as to the fairness, from a financial point of view, to the public stockholders of the Company (excluding Mr. Xinrong Zhuo, the Company’s Chairman and Chief Executive Officer, and his affiliates) of the consideration to be received by the Company in the proposed transaction.

The Board also retained, BMI (www.bmi-appraisals.com) to provide an independent valuation of the vessel operating rights that would constitute a portion of the consideration. BMI is one of the leading valuation companies in Hong Kong and China and has been engaged by more than 1,000 companies, the majority of which are listed companies in Hong Kong, China and overseas. The Board recently received the appraisal report from BMI, which values the right to use 20 new vessels and the licenses to conduct fishing operations, at approximately $216.1 million.

Subsequent to the receipt of the fairness opinion from Duff and Phelps and the BMI appraisal reports, the Board, excluding Mr. Zhuo and Mr. Lin, unanimously voted to approve the proposed transaction.

The Board, excluding Mr. Zhuo and Mr. Lin, will evaluate any potential alternative proposals received during the next 30 days. Assuming the proposed transaction closes, Pingtan would own or have exclusive operating rights to 126 fishing vessels and licenses. At current prices and operating at full capacity, each vessel is expected to generate annual revenue of approximately USD$3 million with annual net income of approximately $800,000 to $1 million.

Company to Receive Operating Rights for Vessels

The proposed transaction includes the transfer of exclusive operating rights for 25 years for each of the 20 new fishing vessels and licenses from Mr. Zhuo to the Company. These 20 fishing vessels received subsidies from China’s central government budget in 2012, and a recent notification from the Government prohibits the sale or transfer of ownership for a period of 10 years for fishing vessels that have received such subsidies.

Below is a link to the above mentioned notification by the Pingtan Government (in Mandarin): http://www.pingtan.gov.cn/xxgk/show.aspx?ctlgid=27147864&Id=8797

About Pingtan

Pingtan is a marine enterprises group, engaging in dredging services and ocean fishing through its wholly-owned subsidiaries, China Dredging Group and Merchant Supreme, and their respective PRC operating subsidiaries, Fujian Xinggang Port Service Co., Ltd., or Fujian Service, Pingtan Xingyi Port Service Co., Ltd., or Pingtan Xingyi and Fujian Provincial Pingtan County Ocean Fishing Group Co., Ltd., or Pingtan Fishing.

Pingtan Fishing primarily engages in ocean fishing with many of its self-owned vessels operating within the Indian Exclusive Economic Zone and the Arafura Sea of Indonesia. Pingtan Fishing is a growing fishing company and provider of high quality seafood in the PRC.

Business Risks and Forward-Looking Statements

This press release may contain forward-looking statements that are subject to the safe harbors created under the Securities Act of 1933 and the Securities Exchange Act of 1934. Readers are cautioned that actual results could differ materially from those expressed in any forward-looking statements. In addition, please refer to the risk factors contained in the Company’s SEC filings available at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Definitive Proxy Statement and Registration Statement on Form S-3. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. Pingtan undertakes no obligation to update or revise any forward-looking statements for any reason.

CONTACT:

Roy Yu
Chief Financial Officer
Pingtan Marine Enterprise Ltd.
Tel: +86 591 87271753
ryu@ptmarine.net

INVESTOR RELATIONS:

The Equity Group Inc.
Adam Prior, Senior Vice President
(212) 836-9606
aprior@equityny.com

In China

Katherine Yao, Associate
86 10 6587 6435
kyao@equityny.com

(HPJ) Delivers EV Battery System to Harbin Institute of Technology

(GOGO) Goes Global: Partners with Japan Airlines to Deliver In-flight Internet

ITASCA, Ill., Oct. 28, 2013 – Gogo (NASDAQ: GOGO), the world leader of in-flight connectivity and a pioneer in wireless in-flight digital entertainment solutions, announced today that it has signed a contract  with Japan Airlines (JAL) to provide Gogo’s in-flight Internet service on JAL’s entire domestic fleet, which consists of 77 aircraft.

“We couldn’t be more excited to work with JAL on bringing Gogo’s connectivity services to JAL’s passengers,” said Gogo’s president and CEO, Michael Small.  “We know from our experience that having connectivity has become a competitive necessity for airlines.  We look forward to providing this service to JAL and keeping its passengers productive, connected and entertained during their travels.”

The new service will utilize Gogo’s Ku-satellite connectivity technology and is expected to be available to JAL passengers beginning in the summer of 2014

“Gogo is the global leader when it comes to in-flight connectivity solutions and we are excited to work with them to be the first Japanese airline to bring Internet service to passengers onboard domestic aircraft,” said Yoshiharu Ueki, JAL’s president. “JAL is continually striving to bring passengers a unique and completely refreshing onboard experience and offering our passengers Internet access on domestic flights is part of that experience.”

About Gogo

Gogo is the global leader of in-flight connectivity and wireless in-flight digital entertainment solutions. Using Gogo’s exclusive products and services, passengers with Wi-Fi enabled devices can get online on more than 2,000 Gogo equipped commercial aircraft. In-flight connectivity partners include American Airlines, Air Canada, AirTran Airways, Alaska Airlines, Delta Air Lines, Frontier Airlines, Japan Airlines, United Airlines, US Airways and Virgin America. In-flight entertainment partners include American Airlines, Delta Air Lines, Scoot and US Airways. In addition to its commercial airline business, Gogo has more than 6,500 business aircraft outfitted with its communications services.

Back on the ground, Gogo’s 600+ employees in Itasca, IL, Broomfield, CO and London are working to continually redefine flying as a productive, socially connected, and all-around more satisfying experience. Connect with Gogo at www.gogoair.com, on Facebook at www.facebook.com/gogo and on Twitter at www.twitter.com/gogo.

(OSN) Announces Receipt of Japanese Industrial Standards Certification

SHANGHAI, Oct. 28, 2013  —

• Important certificate allows Ossen to sell its SWPR7BL prestressed concrete strands in Japan
• R&D for key technology recognized in the Annual Jiangxi Province Science and Technology Award List

Ossen Innovation Co., Ltd. (“Ossen” or the “Company”) (Nasdaq: OSN), a China-based manufacturer of an array of plain surface, rare earth and zinc coated pre-stressed steel materials, today announced that it has been awarded a Japanese Industrial Standards (JIS) certificate. This certification allows Ossen to begin selling its SWPR7BL prestressed concrete strands in Japan. This standardization and certification process, which was completed after a six month in-depth inspection of the Company’s manufacturing facilities and products, was coordinated by the Japanese Industrial Standards Committee, the organization which specifies the standards used for industrial activities in Japan.

“Ossen is very pleased to announce our receipt of this important certification,” said Dr. Liang Tang, Chairman of Ossen Innovation. “The certificate, awarded after rigorous review and testing of our SWPR7BL prestressed concrete strands, affirms the world class quality of our product. We look forward to selling our SWPR7BL prestressed concrete strands in Japan, a market with strict quality controls. Although the Japanese market has high barriers to entry, I am pleased to announce that Ossen has already received indications of interest from one Japanese customer to purchase at least 10,000 tons of our SWPR7BL prestressed concrete strands, with delivery expected in early 2014,” concluded Dr. Tang.

Separately, Ossen’s subsidiary company, Ossen Jiujiang Steel Wire & Cable Co., Ltd., is pleased to announce that its Research and Development (R&D) work on key technology related to the manufacturing of stay cable of large span cable stayed bridges was included in the 2013 Annual Jiangxi Province Science and Technology Award List.

About Ossen Innovation Co., Ltd.

Ossen Innovation Co., Ltd. manufactures and sells a wide variety of plain surface pre-stressed steel materials and rare earth coated and zinc coated pre-stressed steel materials. The Company’s products are mainly used in the construction of bridges, as well as in highways and other infrastructure projects. Ossen has two manufacturing facilities located in Maanshan, Anhui Province, and Jiujiang, Jiangxi Province.

Safe Harbor Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks outlined in the Company’s public filings with the Securities and Exchange Commission, including the Company’s annual report on Form 20-F. All information provided in this press release is as of the date hereof. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

(EDMC) CEO and CFO to Present at J.P. Morgan Ultimate Services Investor Conference

PITTSBURGH, Oct. 25, 2013 – Education Management Corporation (NASDAQ: EDMC), a leading provider of post-secondary education, announced today that Edward H. West, president and CEO, and Mick J. Beekhuizen, executive vice president and CFO, are scheduled to participate in the J.P. Morgan Ultimate Services Investor Conference in New York City on Wednesday, Nov. 13, 2013 at 11:30 a.m. Eastern Time.

Interested parties can access a live webcast of the presentation on the Investor Relations section of the Education Management website (www.edmc.edu).  An archive of the webcast and a copy of the presentation will also be available on the Investor Relations section of the company’s website (www.edmc.edu).

About Education Management
Education Management (www.edmc.edu), with approximately 132,000 students as of October 2012, is among the largest providers of post-secondary education in North America, based on student enrollment and revenue, with a total of 110 locations in 32 U.S. states and Canada.  We offer academic programs to our students through campus-based and online instruction, or through a combination of both. We are committed to offering quality academic programs and continuously strive to improve the learning experience for our students.  Our educational institutions offer students the opportunity to earn undergraduate and graduate degrees and certain specialized non-degree diplomas in a broad range of disciplines, including design, media arts, health sciences, psychology and behavioral sciences, culinary, fashion, business, education, legal and information technology.

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements typically contain words such as “anticipates,” “believes,” “estimates,” “expects,” “intends” or similar words indicating that future outcomes are not known with certainty and are subject to risk factors that could cause these outcomes to differ significantly from those projected. Forward-looking statements include, but are not limited to, statements related to the company’s future operating and financial performance, and include statements regarding expected enrollment, revenue, expense levels, capital expenditures and earnings. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results encompassed within the forward-looking statements. Some of the factors that could cause actual results to differ materially include, but are not limited to: changes in the overall U.S. or global economy; changes in enrollment or student mix; our ability to maintain eligibility to participate in Title IV programs; increased or unanticipated legal and regulatory costs; success of cost-cutting initiatives and growth strategies; changes in accreditation standards; the implementation of new operating procedures for our fully online programs; government and regulatory changes including revised interpretations of regulatory requirements that affect the postsecondary education industry; new programs and operational changes implemented in response to the “gainful employment” financial metrics; the potential impact of the draft “gainful employment” regulation issued by the U.S. Department of Education on August 30, 2013; and other factors discussed in our filings with the Securities and Exchange Commission, including those identified in the “Risk Factors” section of our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Past results of Education Management are not necessarily indicative of its future results. Education Management does not undertake any obligation to update any forward-looking statements, except as required by securities law.

FOR: Education Management Corporation

(IMMU) Epratuzumab Featured in Official Journal of The American Society of Hematology

MORRIS PLAINS, N.J., Oct. 25, 2013  — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that an article published yesterday in Blood described a mechanism by which epratuzumab affects B cells. Epratuzumab is a humanized anti-CD22 antibody currently in Phase III trials conducted by the Company’s corporate partner, UCB (Euronext Brussels:UCB), as a therapeutic for patients with systemic lupus erythematosus (lupus).

The article was authored by several scientists of the Company, as well as a clinical collaborator, Dr. Daniel J. Wallace of Cedars-Sinai Medical Center of UCLA in Los Angeles, CA. The article was featured on the cover of this issue of Blood with a fluorescence microscopy image, showing how epratuzumab can translocate certain surface proteins on B cells to other blood cells, a process called trogocytosis.

Accompanying the article was an invited commentary by Dr. Ronald P. Taylor of the University of Virginia School of Medicine, who is a pioneer on studies of trogocytosis involving anti-B-cell antibodies, such as rituximab.

In the article by Rossi and colleagues of Immunomedics, it was demonstrated that epratuzumab can induce trogocytosis of CD22, CD21, CD19, and several other B-cell surface molecules from lymphocytes to other blood cells, such as monocytes, natural killer cells, and granulocytes. Epratuzumab is distinct from other B-cell antibodies, such as rituximab, because it does not drastically deplete B cells, but instead compromises B-cell autoimmune activity.

The Immunomedics scientists postulated that removal of CD22, CD19, CD21 and other proteins from the surface of B cells reduces the autoimmune activity of these cells. In fact, B cells obtained from lupus patients who were treated with epratuzumab showed reduced CD22, CD19 and CD21. The authors suggest that this modulation of B cells via trogocytosis could be the major mechanism of epratuzumab in patients with lupus.

Cynthia L. Sullivan, President and CEO of Immunomedics, commented: “We are gratified that we have advanced our knowledge on how epratuzumab, which is completing Phase III trials in patients with moderate and severe lupus, may affect antigen-presenting B cells in this autoimmune disease without having a major depletion of this population of blood cells needed to protect individuals from infections. Having an effect of down-regulating CD19, CD21, and other surface molecules on B cells, is an unexpected finding, and is consistent with the view by some that CD19 is a key molecule that is increased in autoimmune disease.”

About Systemic Lupus Erythematosus (SLE)

SLE or lupus, is a complex, systemic, autoimmune disease that affects many different organ systems, including the skin, joints, lungs, kidneys and blood. Disease activity and rate of progression of organ system damage is highly variable. SLE affects from 20 to 70 people per 100,000 population, and is rare in childhood. It is 10 times more common in women than men.

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Our lead product candidate, epratuzumab, is currently in two Phase III clinical trials in lupus. In oncology, we are planning to launch a Phase III pivotal trial for clivatuzumab labeled with a radioisotope in advanced pancreatic cancer patients. Other solid tumor therapeutics in Phase II clinical development include 2 antibody-drug conjugates, labetuzumab-SN-38 (IMMU-130) and hRS7-SN-38 (IMMU-132). We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel DOCK-AND-LOCK™ (DNL™) method with us for making fusion proteins and multifunctional antibodies. DNL™ is being used particularly to make bispecific antibodies targeting cancers and infectious diseases as a T-cell redirecting immunotherapy, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies. We believe that our portfolio of intellectual property, which includes approximately 231 active patents in the United States and more than 400 foreign patents, protects our product candidates and technologies. Our strength in intellectual property has resulted in the top-10 ranking in the 2012 IEEE Spectrum Patent Power Scorecards in the Biotechnology and Pharmaceuticals category. For additional information on us, please visit our website at www.immunomedics.com. The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with any cash payment that the Company might receive in connection with a sublicense involving a third party and UCB, which is not within the Company’s control, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on UCB for the further development of epratuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Dr. Chau Cheng
         Senior Director, Investor Relations & Grant Management
         (973) 605-8200, extension 123
         ccheng@immunomedics.com

(AERI) Announces Pricing of Initial Public Offering

Aerie Pharmaceuticals, Inc., announced today the pricing of its initial public offering of 6,720,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts. The shares are scheduled to begin trading on the NASDAQ Global Market on October 25, 2013 under the ticker symbol “AERI.” In addition, Aerie has granted the underwriters a 30-day option to purchase up to an additional 1,008,000 shares of common stock at the same price to cover over-allotments, if any.

The offering is expected to close on October 30, 2013, subject to customary closing conditions.

RBC Capital Markets and Stifel are serving as joint book-running managers for the offering. Canaccord Genuity Inc. and Needham & Company are serving as co-managers.

A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on October 24, 2013. This offering is being made only by means of a prospectus. A copy of the prospectus can be obtained from RBC Capital Markets, LLC, Attention: Equity Syndicate, Three World Financial Center, 200 Vesey Street, 8th Floor, New York, New York 10281, or by telephone at (877) 822-4089, or from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at (415) 364-2720.

This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

Aerie’s lead product candidate, AR-13324, is the first of a new dual-action drug class that was discovered by Aerie scientists. AR-13324 is a once-daily eye drop designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. Aerie’s product candidate PG324 is a fixed combination of dual-action AR-13324 with latanoprost formulated in a single eye drop and is designed to lower intraocular pressure by reducing fluid inflow while also opening both of the eye’s fluid drains.

Aerie is located in Bedminster, New Jersey, Research Triangle Park, North Carolina, and Newport Beach, California.

(CLPI) Subsidiary Money-on-Mobile Gets Reserve Bank of India Five Year Renewal

The Reserve Bank of India (RBI) today announced formally that Money-on-Mobile subsidiary, My Mobile Payments Ltd., has received a five year renewal of its authorization to operate a mobile payments system in the country.

Money-on-Mobile (MoM) is the largest provider of mobile currency transactions in India with over 71 million unique users and over 163,000 participating retail locations as of September 31, 2013. Money-on-Mobile CEO Shashank Roshi stated, “The license granted to Money-on-Mobile was originally for 2 years and is now renewed for 5 years. This displays the regulator’s confidence in our ability to bring more consumers to the digital paperless payment platform, in turn helping the RBI realize their goal of a 70% paperless transactions consumer economy.”

About Calpian, Inc.

Calpian, Inc. (OTC:CLPI) is a publicly traded company with corporate offices in Dallas, Texas, operating centers in Georgia, and New York and mobile payments emerging-market operations through its subsidiary in India. Calpian’s Indian subsidiary offers Money-on-Mobile, a pre-paid mobile payment solution, to more than 163,000 Indian retail locations. Calpian’s management team has over 70 years in combined experience in the payments business. Please visit our website at www.calpian.com.

(URG) Closes US$34,000,000 State Bond Loan, Retires Earlier Debts

LITTLETON, Colo., Oct. 24, 2013 — Ur-Energy Inc. (TSX: URE, NYSE MKT: URG) (“Ur‑Energy” or the “Company”) is pleased to announce that the Company, through its wholly-owned subsidiary Lost Creek ISR, LLC, has closed the previously announced US$34 million Sweetwater County, State of Wyoming, Taxable Industrial Development Revenue Bond (the “State Bond Loan”).

The State Bond Loan calls for payments of interest at a fixed rate of 5.75% per annum on a quarterly basis commencing January 1, 2014.  The principal is payable in 28 quarterly installments which do not commence until January 1, 2015.  The loan matures in October 2021.  The State Bond Loan is secured by the assets of the Lost Creek Project.  Closing and other fees and expenses for the State Bond Loan totaled approximately 2.3% of the loan amount.

Ur-Energy President and CEO Wayne Heili said, “I am very pleased to announce the successful completion of this funding.  It is a testament to the viability of the Lost Creek project that it can stand up to the State’s lengthy and rigorous due diligence process.  Converting the Company’s debt instruments to the more favorable State Bond Loan provides a manageable debt service schedule that will serve the Company and its shareholders well.  Ongoing operations at the Lost Creek Project will provide Ur-Energy with the opportunity to advance its Wyoming growth strategy.”  Heili added, “I would like to thank the Sweetwater County Commissioners for their demonstrated support of the Lost Creek Project as well as Governor Matt Mead, State Treasurer Mark Gordon and the Wyoming Business Council. Their determination to utilize this State program, which is funded by the State’s Permanent Mineral Trust Fund, for our Lost Creek uranium project demonstrates the current administration’s dedication to our State’s energy economy.  As a productive part of that economy, Ur-Energy and its 75 Wyoming employees exemplify the type of project the Industrial Development Revenue Bond Program was designed for.”

The closing of the State Bond Loan permitted the retirement of the Company’s debts with RMB Australia Holdings Ltd. (“RMBAH”).  The two RMBAH loan facilities served as interim financing to complete construction at Lost Creek and begin production uninterrupted while the State Bond Loan was advanced to closing.  The early repayment of the second loan facility triggered a rebate of half of the arrangement fee paid by the Company (US$450,000 credited) while half of the warrants issued in relation to that loan were also cancelled (1,500,400 warrants for common shares cancelled).  A portion of the RMBAH first loan facility remains available to the Company to be redrawn for specified purposes.  Roger Smith, CFO of Ur-Energy, stated, “We would again like to express our appreciation to RMB for its commitment to our project and company.  We look forward to working with this well-respected international banking partner on future opportunities.”

Lost Creek Production Update
The Company’s Lost Creek Project, which commenced production operations in August 2013, has now commissioned the first three header houses in Mine Unit 1 and all of the production circuits in the processing plant.  The first dried yellowcake (uranium oxide) was recently drummed and packaged at Lost Creek.  Additional details will be provided in the Company’s forthcoming quarterly financial reports.

About Ur-Energy
Ur-Energy is a junior uranium mining company operating the Lost Creek in-situ recovery uranium facility in south-central Wyoming.  The Lost Creek processing facility has a two million pounds per year nameplate capacity with a one million pound annual rate planned from the mining areas at Lost Creek.  Ur-Energy engages in the identification, acquisition, exploration development, and operation of uranium projects in the United States and Canada.  Shares of Ur-Energy trade on the Toronto Stock Exchange under the symbol “URE” and on the NYSE MKT under the symbol “URG”. Ur-Energy’s corporate office is located in Littleton, Colorado; its registered office is in Ottawa, Ontario.  Ur-Energy’s website is www.ur-energy.com.

FOR FURTHER INFORMATION, PLEASE CONTACT

This release may contain “forward-looking statements” within the meaning of applicable securities laws regarding events or conditions that may occur in the future (e.g., continued ramp-up of operations at Lost Creek; manageability of debt service; success of the company’s growth strategy) and are based on current expectations that, while considered reasonable by management at this time, inherently involve a number of significant business, economic and competitive risks, uncertainties and contingencies. Factors that could cause actual results to differ materially from any forward-looking statements include, but are not limited to, capital and other costs varying significantly from estimates; failure to establish estimated resources and reserves; the grade and recovery of ore which is mined varying from estimates; production rates, methods and amounts varying from estimates; delays in obtaining or failures to obtain required governmental, environmental or other project approvals; inflation; changes in exchange rates; fluctuations in commodity prices; delays in development and other factors. Readers should not place undue reliance on forward-looking statements. The forward-looking statements contained herein are based on the beliefs, expectations and opinions of management as of the date hereof and Ur-Energy disclaims any intent or obligation to update them or revise them to reflect any change in circumstances or in management’s beliefs, expectations or opinions that occur in the future.

(BSDM) Reports Increasing European Market Penetration

BSD Medical Corporation (NASDAQ: BSDM) (“Company” or “BSD”) today reported that Terumo Europe NV (Terumo), a wholly owned subsidiary of Terumo Corporation, has already introduced the MicroThermX^® Microwave Ablation System (MicroThermX) into the major markets in Europe, including Germany, France and Spain.

Terumo has performed numerous clinical procedures throughout Europe, which has led to enhanced clinical acceptance and greater market penetration. The market potential in the 100 countries included in the Terumo contract is in excess of $1 billion in annual sales. As a result of the increased clinical acceptance, Terumo continues to increase their purchases of MicroThermX generators and antennas.

“Terumo has made a substantial investment in commercialization of the MicroThermX, and their market penetration has already exceeded our expectations. There is a critical need for innovative, cost-effective cancer treatment technologies throughout the world due to the increasing cost of health care,” said Sam Maravich, Vice President of Sales and Marketing for BSD. “The MicroThermX system is innovative and cost-effective. Our technology allows the clinician to treat multiple types and sizes of tumors with one minimally invasive system, which significantly reduces procedure cost and complexity. The healthcare systems in the majority of European countries are structured to facilitate fast adoption of minimally invasive, efficacious, cost-effective, advanced technology like the MicroThermX.”

About Terumo Corporation

A world leader in state-of-the-art medical devices and interventional oncology, Tokyo-based Terumo Corporation (TYO: JP:4543) reported 2013 sales of nearly $5 billion and has a market cap in excess of $8 billion. Through the sale and promotion of a high quality line of devices used for tumor embolization, the closing or blocking of blood vessels, Terumo Europe NV has established itself as a pioneer in the field of interventional oncology.

About the MicroThermX^® Microwave Ablation System

The MicroThermX is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide a wide range of uniform zones of ablation. The MicroThermX includes innovative, high-end disposables (SynchroWave antennas) that are used in each ablation treatment and will provide a significant ongoing revenue stream. The soft tissue (tumor) ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX System, which allows BSD to market the MicroThermX in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX to a number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical’s website at www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.

(OPTT) and Mitsui Engineering Announce Agreement to Commercialize PowerBuoys®

PENNINGTON, N.J., Oct. 24, 2013  — Ocean Power Technologies, Inc. (Nasdaq:OPTT) (“OPT” or the “Company”) and Mitsui Engineering & Shipbuilding Co., Ltd. (“MES”) today announced that they have signed a new agreement to cooperate in the development and commercialization of OPT’s PowerBuoy^® technology.

Building on the successful work previously done together by the companies, this agreement sets forth the terms of technology licensing and other financial arrangements between MES and OPT regarding OPT’s PowerBuoy systems. Under the terms of the agreement, MES has the licensed right to sell OPT’s PowerBuoys for both grid-connected utility and autonomous applications in Japan, the Philippines, Malaysia, Vietnam, Mozambique, South Africa and Namibia. The license provides for a renewable 10-year term under which MES has the exclusive right to manufacture and sell PowerBuoys in its territory, for which sales OPT will receive royalty payments. Under terms to be agreed by MES and OPT, OPT also will sell to MES the Power Take-Off systems to be integrated in all PowerBuoys sold by MES. Furthermore, MES will receive commission payments for any customers outside its territory that MES refers to OPT. Recognizing MES’s manufacturing capabilities and expertise in the building of ships and offshore platforms, MES has the first refusal right to manufacture PowerBuoys sold outside its territory, subject to certain exceptions.

Mr. Hirotaka Ohashi, Deputy Director of Business Development and Innovation Hq. at MES, said, “We are very pleased to enter into this important agreement with OPT to develop new business opportunities for the PowerBuoy technology. MES looks forward to continuing to work with OPT, and we believe that wave energy is important to our vision of reducing dependence on fossil fuels.”

“This agreement between OPT and MES marks a significant milestone in the commercialization of our technology,” said Mr. Charles F. Dunleavy, Chief Executive Officer of OPT. “We are very excited to build on the work we have done over the past several years with MES, and we appreciate this recognition of the great business opportunity provided by our PowerBuoys, for both grid-connected and autonomous applications.”

The agreement also documents the understanding between OPT and MES regarding the use of existing intellectual property and any improvements expected to be created by the parties during the term of the agreement.

Forward-Looking Statements

This release may contain “forward-looking statements” that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company’s current expectations about its future plans and performance, including statements concerning the manufacture, marketing and sale of the Company’s products, the performance of the parties under the agreement, and the on-going relationship with MES. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company’s most recent Form 10-K for a further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.

About Ocean Power Technologies

Ocean Power Technologies, Inc. (Nasdaq:OPTT) is a pioneer in wave-energy technology that harnesses ocean wave resources to generate reliable and clean and environmentally-beneficial electricity. OPT has a strong track record in the advancement of wave energy and participates in an estimated $150 billion annual power generation equipment market. OPT’s proprietary PowerBuoy® system is based on modular, ocean-going buoys that capture and convert predictable wave energy into clean electricity. The Company is widely recognized as a leading developer of on-grid and autonomous wave-energy generation systems, benefiting from more than 15 years of in-ocean experience. OPT is headquartered in Pennington, New Jersey, USA with an office in Warwick, UK, and operations in Melbourne and Perth, Australia. More information can be found at www.oceanpowertechnologies.com.

About Mitsui Engineering & Shipbuilding Co., Ltd.

The principal business of Mitsui Engineering & Shipbuilding (“MES”) is machinery and shipbuilding. With annual revenues in excess of $8.0 billion, MES’s activities include manufacturing and sales of various types of industrial machinery, such as engines, boilers, gas turbines and robotic systems, and plant construction for water and waste treatment facilities, bridges, and watergates. Its shipbuilding business comprises a broad array of natural resource carriers and double hull tankers. MES is a publicly-held company with over 10,000 employees.

CONTACT: Ocean Power Technologies, Inc.
         Charles F. Dunleavy, Chief Executive Officer
         Telephone: +1 609 730 0400

(JMSN) Closes Series B Bridge Financing

(HOTR) Executes Stock Purchase Agreement for Nottingham, England Hooters Location

(IMMU) 90 Y-Clivatuzumab Tetraxetan With Gemcitabine Active in Late-Stage Pancreatic Cancer

LYON, France, Oct. 23, 2013 — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that multiple cycles of therapy with the Company’s pancreatic cancer therapeutic, clivatuzumab tetraxetan labeled with yttrium-90 (⁹⁰Y), in combination with low-dose gemcitabine, produced a median overall survival (OS) of more than 5 months in patients with metastatic pancreatic cancer who had received at least 2 prior treatments.

Results from the Phase Ib clinical trial were updated by Dr. William A. Wegener, Senior Vice President, Clinical Research, in an oral presentation at the 26^th Annual Congress of the European Association of Nuclear Medicine in Lyon, France.

Despite a difficult-to-treat patient population with relapsing disease, a partial response in 53 CT-assessable patients was reported at the Congress. In addition, median OS for patients with partial response or stable disease as best response was longer than those with disease progression (131 days vs. 66 days, respectively).

“Based on these encouraging results, which have to be confirmed with a Phase III clinical trial, we are proceeding with our plan to initiate such trial with clivatuzumab in this late-stage disease setting,” commented Cynthia L. Sullivan, President and Chief Executive Officer. “We are preparing to open this pivotal study before the end of 2013 or the beginning of 2014,” Ms. Sullivan added.

With the acronym PANCRIT, which stands for PANcreatic Cancer RadioImmunotherapy Trial, the Phase III study will be a double-blind, randomized trial of ⁹⁰Y-clivatuzumab tetraxetan with low-dose gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer patients who have progressed on at least 2 prior therapies, 1 of which must be a gemcitabine-containing regimen.

Target enrollment for this multicenter, international trial is 440 patients. A majority of these patients will be recruited at clinical sites across the U.S., with additional sites in Canada, Europe and Israel participating. Patients will be randomized 2 to 1 to the treatment arm.

Primary endpoint of PANCRIT will be overall survival, with objective response, progression-free survival and clinical benefit such as quality of life serving as secondary outcome measures.

About Pancreatic Cancer

According to the American Cancer Society, an estimated 45,220 Americans will be diagnosed with pancreatic cancer in 2013, making it the 10^th most common cancer diagnosis among men and the 9^th most common among women in the U.S. It is, however, the fourth leading cause of cancer death among both men and women nationwide, with approximately 38,460 deaths expected, or about 7% of all cancer deaths.

The outlook for pancreatic cancer patients is bleak, with median survival ranges from 4.5 months for the most advanced stage to 24.1 months for the earliest stage. For patients with the advanced disease, treatment options are limited to gemcitabine alone or in combination with other agents. Although FOLFIRINOX, the drug combination of leucovorin, fluorouracil, irinotecan, and oxaliplatin, has recently been shown to prolong survival in patients with newly-diagnosed advanced disease, many patients could not tolerate this treatment regimen.

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Our lead product candidate, epratuzumab, is currently in two Phase III clinical trials in lupus. In oncology, we are planning to launch a Phase III pivotal trial for clivatuzumab labeled with a radioisotope in advanced pancreatic cancer patients. Other solid tumor therapeutics in Phase II clinical development include 2 antibody-drug conjugates, labetuzumab-SN-38 (IMMU-130) and hRS7-SN-38 (IMMU-132). We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel DOCK-AND-LOCK™ (DNL™) method with us for making fusion proteins and multifunctional antibodies. DNL™ is being used particularly to make bispecific antibodies targeting cancers and infectious diseases as a T-cell redirecting immunotherapy, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies. We believe that our portfolio of intellectual property, which includes approximately 231 active patents in the United States and more than 400 foreign patents, protects our product candidates and technologies. Our strength in intellectual property has resulted in the top-10 ranking in the 2012 IEEE Spectrum Patent Power Scorecards in the Biotechnology and Pharmaceuticals category. For additional information on us, please visit our website at www.immunomedics.com. The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with any cash payment that the Company might receive in connection with a sublicense involving a third party and UCB, which is not within the Company’s control, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on UCB for the further development of epratuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Dr. Chau Cheng
         Senior Director, Investor Relations & Grant Management
         (973) 605-8200, extension 123
         ccheng@immunomedics.com

(CECO) Adds Three Experienced Education Professionals To Key Positions

Career Education Corporation (NASDAQ: CECO), a global provider of postsecondary education programs and services, today announced the appointment of three experienced education professionals to key positions.

Jim McCoy joins as Vice President of Operations – Career Schools, overseeing all aspects of Career Education’s Design & Technology and Health campuses. McCoy worked for nearly 20 years at Strayer University, serving most recently as Senior Vice President of Operations, effectively running an organization with dozens of campuses serving thousands of students across multiple states. His experience includes centralization of Strayer’s business office operations while improving operational and academic performance, enrollment growth, student satisfaction, policy compliance and financial performance. He is tasked with achieving performance efficiency and quality gains that help deliver excellent education to students.

Ann Berger joins American InterContinental University as Vice President of Educational Alliances, focused on, among other things, building national accounts with companies looking for educational partnerships to offer their employees. Berger worked for Strayer University for nearly nine years, during which time she built alliances with companies, government and other education institutions to attract more students. She grew national accounts and signed articulation agreements with more than 150 two-year community colleges, leading to enrollment growth from transfer students. Most recently she was Vice President of Business Development for Educate Online in Baltimore, Md.

Dr. Jim Chitwood joins Career Education as Vice President of Enrollment Management, overseeing admissions operations for Career Schools, including Design & Technology, Health and Culinary campuses. Chitwood will oversee the entire student enrollment lifecycle, from taking new applications and starting new students, to retaining students through to graduation by reducing attrition. Chitwood’s experience includes serving as president of Ashford University in Clinton, Iowa, as a campus president for Argosy University, overseeing various state operations for the University of Phoenix and as a Vice President at a third-party service provider of marketing, admissions, finance and operations services to traditional higher education institutions.

About Career Education Corporation

The colleges, schools and universities that are part of the Career Education Corporation family offer high-quality education to a diverse student population across the world in a variety of career-oriented disciplines through online, on-ground and hybrid learning program offerings. The campuses that serve these students are located throughout the United States and in France, the United Kingdom and Monaco, and offer doctoral, master’s, bachelor’s and associate degrees and diploma and certificate programs.

Career Education is an industry leader whose institutions are recognized globally. Those institutions include, among others, American InterContinental University (“AIU”); Brooks Institute; Colorado Technical University (“CTU”); Harrington College of Design; INSEEC Group (“INSEEC”) Schools; International University of Monaco (“IUM”); International Academy of Design & Technology (“IADT”); Le Cordon Bleu North America (“LCB”); and Sanford-Brown Institutes and Colleges. Through its schools, Career Education is committed to providing high-quality education, enabling students to graduate and pursue rewarding career opportunities.

For more information, see Career Education’s website at www.careered.com. The website includes a detailed listing of individual campus locations and web links to Career Education’s colleges, schools, and universities.